New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
16:48 EDTAEGRAegerion reports Q2 EPS (6c), consensus (41c)
Reports Q2 revenue $36M, consensus $35.4M.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
18:39 EDTAEGROn The Fly: After Hours Movers
Subscribe for More Information
17:05 EDTAEGRAegerion drops 32% to $23.35 after lowering sales outlook
Aegerion said in its earnings release, ""We continue to believe in the overall market potential of JUXTAPID. However, we are reducing our full year's sales estimates at this time to reflect both higher patient dropout rates and lower U.S. prescription growth rates than previously anticipated following the commercial investments we made earlier this year. In addition, while the foundation of our ex-U.S. infrastructure has been built, we continue to face various geographic reimbursement challenges, such as in Sao Paolo, Brazil, and more lengthy reimbursement delays in countries such as Mexico, Canada and Taiwan than we anticipated."
16:37 EDTAEGRAegerion expects FY15 revenue growth 30%-40% vs FY14, consensus $291.75M
Subscribe for More Information
16:36 EDTAEGRAegerion lowers FY14 JUXTAPID product sales guidance to $150M-$160M
Subscribe for More Information
16:35 EDTAEGRAegerion reports Q3 EPS (20c), consensus (14c)
Subscribe for More Information
15:30 EDTAEGRNotable companies reporting after market close
Subscribe for More Information
October 29, 2014
09:28 EDTAEGRAegerion board backs CEO amid drug claims, TheStreet reports
Subscribe for More Information
October 27, 2014
10:52 EDTAEGRSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information
October 22, 2014
07:35 EDTAEGRCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use